ATE541565T1 - Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus - Google Patents

Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus

Info

Publication number
ATE541565T1
ATE541565T1 AT00936383T AT00936383T ATE541565T1 AT E541565 T1 ATE541565 T1 AT E541565T1 AT 00936383 T AT00936383 T AT 00936383T AT 00936383 T AT00936383 T AT 00936383T AT E541565 T1 ATE541565 T1 AT E541565T1
Authority
AT
Austria
Prior art keywords
tinnitus
muscarinic
treatment
topical use
opioid agents
Prior art date
Application number
AT00936383T
Other languages
English (en)
Inventor
Khoury George F El
Original Assignee
Khoury George F El
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khoury George F El filed Critical Khoury George F El
Application granted granted Critical
Publication of ATE541565T1 publication Critical patent/ATE541565T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00936383T 1999-05-27 2000-05-26 Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus ATE541565T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31857399A 1999-05-27 1999-05-27
PCT/US2000/014727 WO2000072835A2 (en) 1999-05-27 2000-05-26 Topical application of muscarinic and opioid agents for treatment of tinnitus

Publications (1)

Publication Number Publication Date
ATE541565T1 true ATE541565T1 (de) 2012-02-15

Family

ID=23238739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00936383T ATE541565T1 (de) 1999-05-27 2000-05-26 Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus

Country Status (5)

Country Link
US (2) US6262063B1 (de)
EP (1) EP1814532B1 (de)
AT (1) ATE541565T1 (de)
AU (1) AU5170400A (de)
WO (1) WO2000072835A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
EP1190709A1 (de) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Behandlung von Tinnitus
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
WO2004089357A2 (en) * 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US20070021804A1 (en) * 2003-05-30 2007-01-25 Maltan Albert A Stimulation using a microstimulator to treat tinnitus
AU2006316607A1 (en) * 2005-11-21 2007-05-31 Schering-Plough Pty. Limited Pharmaceutical compositions comprising buprenorphine
SI2170279T1 (en) * 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
RU2687249C2 (ru) * 2013-05-03 2019-05-08 Томас М. КРЮС Способ лечения заболевания с помощью аурикулярной анестезии черепных нервов
US20140335021A1 (en) * 2013-05-13 2014-11-13 Mustafa A.M. Salih Ocular Neostigmine Drops for Diagnosing Myasthenia Gravis
CN107072940A (zh) * 2014-07-29 2017-08-18 奥德纳米有限公司 用于治疗耵聍分泌过多的耳用制剂
WO2020163588A1 (en) * 2019-02-08 2020-08-13 Board Of Trustees Of Southern Illinois University Neuronal nicotinic acetylcholine receptor partial agonists as therapeutics for chronic tinnitus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469702A (en) * 1981-06-23 1984-09-04 Schulte Thomas L Analgesic composition and use thereof to ameliorate deep and intractable pain
US4369190A (en) 1981-06-23 1983-01-18 Schulte Thomas L Analgesic composition and use thereof to ameliorate intractable pain
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
US5697975A (en) 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
JP4097285B2 (ja) * 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
ES2174337T3 (es) * 1996-12-16 2002-11-01 Alcon Lab Inc Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
AU7450898A (en) * 1997-05-28 1998-12-30 Tokyo Tanabe Company Limited Indole compounds
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
WO2000071518A2 (en) * 1999-05-25 2000-11-30 Sepracor, Inc. Heterocyclic analgesic compounds and their use

Also Published As

Publication number Publication date
US20020010191A1 (en) 2002-01-24
US6262063B1 (en) 2001-07-17
WO2000072835A2 (en) 2000-12-07
EP1814532B1 (de) 2012-01-18
AU5170400A (en) 2000-12-18
EP1814532A2 (de) 2007-08-08
WO2000072835A3 (en) 2002-03-21
US6465442B2 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
BR0312232A (pt) Inibidores de caspases e seus usos
ATE515253T1 (de) Zusammensetzungen auf basis von etyllinoleat und triethylcitrat zur behandlung von seborrhöe und akne
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE345793T1 (de) Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs